Mode
Text Size
Log in / Sign up

Retatrutide Demonstrates Dose Dependent Glycemic Control and Weight Loss in Type 2 DiabetesTrial shows retatrutide improves blood sugar and weight in diabetes

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Retatrutide shows dose-dependent HbA1c reduction and significant weight loss in adults with type 2 diabetes.

This Phase 3 randomized controlled trial evaluated the efficacy and safety of retatrutide, a multi-agonist, in patients with type 2 diabetes who had inadequate glycemic control despite lifestyle modifications. The study enrolled 537 adults with HbA1c levels between 7.0% and 9.5% and a BMI of at least 23 kg/m. Participants were randomized to receive one of three doses of retatrutide (4 mg, 9 mg, or 12 mg) via once-weekly subcutaneous injection or a placebo over a 40-week period.

The primary endpoint was the change in HbA concentration from baseline to week 40. Results indicated that all retatrutide dose groups achieved statistically significant reductions in HbA1c compared to the placebo group. Specifically, the 4 mg dose resulted in a -1.69% reduction (difference of -0.88% vs placebo), while the 9 mg and 12 mg doses yielded reductions of -1.86% and -1.94%, respectively. These results suggest a clear dose-dependent improvement in glycemic control.

Secondary outcomes focused on bodyweight percentage change, which also demonstrated significant improvements across all active treatment arms. Patients receiving the 4 mg dose lost 11.5% of their body weight, while those on the 9 mg and 12 mg doses experienced reductions of 13.9% and 15.3%, respectively. In contrast, the placebo group saw only a 2.6% reduction in bodyweight. These findings highlight retatrutide's potential for managing both glucose levels and obesity in this patient population.

Safety profiles were consistent with other agents possessing GLP-1 agonist activity. The most common adverse events were gastrointestinal in nature, typically described as mild to moderate and decreasing in frequency over the course of treatment. While two deaths occurred in the 4 mg cohort, investigators determined these were not related to the study medication. Discontinuation rates due to adverse events were low, ranging between 2% and 5% for retatrutide groups.

From a clinical perspective, retatrutide presents a robust profile for managing type 2 diabetes. The significant reduction in HbA1c across all doses suggests it can be an effective monotherapy for patients requiring improved glycemic control. Furthermore, the substantial weight loss observed may improve long-term outcomes for patients with comorbid obesity. The high certainty of these results stems from the large sample size and clear dose-response relationship.

Clinicians should note that while gastrointestinal effects are common, they appear manageable over time. Retatrutide provides a potent pharmacological option for patients who do not achieve targets through diet and exercise alone. The data supports its role in improving metabolic health by addressing both the primary pathology of diabetes and the associated weight management challenges.

How this fits prior evidence

How this fits prior evidence: This study provides new data on a multi-agonist approach for type 2 diabetes. It addresses a gap in monotherapy options that combine significant weight loss with glycemic control, unlike resveratrol which showed no consistent impact on glycemic indices. While it differs from the surgical intervention of a sleeve plus bypass, it offers a pharmacological alternative for metabolic improvement in patients with obesity and T2DM.

Managing type 2 diabetes can be a daily challenge, especially when diet and exercise alone are not enough to keep blood sugar levels in a healthy range. For many people living with this condition, finding a treatment that addresses both high blood sugar and the associated weight management issues is a major goal for improving long-term health.

A large clinical trial was conducted to test a new medication called retatrutide. The study included 537 adults who had type 2 diabetes and were not meeting their goals through lifestyle changes alone. These participants were divided into groups to receive either a weekly injection of retatrutide at different doses (4 mg, 9 mg, or 12 mg) or a placebo (a dummy treatment with no active medicine). The study lasted for 40 weeks to see how the medication affected their health.

The results showed that retatrutide was effective in helping patients manage their condition. Compared to those who took the placebo, people taking retatrutide saw significant drops in their HbA1c levels—a key measure of average blood sugar over several months. Specifically, those on the highest dose (12 mg) saw a reduction of 1.94% in their HbA1c levels compared to just 0.81% for those on the placebo. Additionally, the medication led to notable weight loss. Participants taking the 12 mg dose lost about 15.3% of their body weight, while those on the 4 mg dose lost 11.5%. These results suggest that retatrutide can be an effective way to manage both blood sugar and weight simultaneously.

In terms of safety, most people who took the medication experienced mild to moderate side effects, primarily involving the digestive system. These issues typically lessened over time as the body adjusted to the medicine. While there were two deaths reported in one group, investigators confirmed they were not related to the drug itself. Only a small number of people chose to stop taking the medication due to these side effects.

It is important to keep these results in perspective. While the findings are promising, this was a single study involving a specific group of people over 40 weeks. Because it is a new treatment, more long-term data will be needed to see how it works over several years. Furthermore, while weight loss and better blood sugar levels are significant markers of success, every patient's experience with new medications can vary based on their unique health history. For patients today, this means that retatrutide shows great potential as a treatment option for type 2 diabetes. It offers a way to manage the disease while also addressing weight, which is often a core part of the struggle for many patients. You should speak with your doctor to discuss if this new class of medication fits into your personal treatment plan.

What this means for you:
Retatrutide significantly lowered blood sugar and helped with weight loss in adults with type 2 diabetes.

Study Details

Study typeRct
Sample sizen = 930
EvidenceLevel 2
Follow-up9.2 mo
PublishedJun 2026
View Original Abstract ↓
BACKGROUND: Retatrutide is a GIP, GLP-1, and glucagon triple hormone receptor agonist, under clinical development for type 2 diabetes, obesity, and related complications. We aimed to assess the efficacy and safety of retatrutide as a monotherapy in people with type 2 diabetes that is inadequately controlled by diet and exercise alone. METHODS: In this 40-week, phase 3, randomised, double-blind, placebo-controlled trial at 48 sites in the USA, Mexico, and India, we recruited adults (aged ≥18 years) with type 2 diabetes that is inadequately controlled by diet and exercise alone, glycated haemoglobin (HbA) between 7·0% and 9·5% (53-80 mmol/mol), and BMI of at least 23 kg/m. Participants were randomly assigned (1:1:1:1) to receive retatrutide (4 mg, 9 mg, or 12 mg) or placebo by once-weekly subcutaneous injection. The primary endpoint was the change in HbA concentration from baseline to week 40. A key secondary endpoint was the percentage change in bodyweight from baseline to week 40. This trial is registered with ClinicalTrials.gov, NCT06354660, and is completed. FINDINGS: Between April 10, 2024, and April 21, 2025, 930 participants were screened and 537 (296 [55%] female and 241 [45%] male) were randomly assigned: 134 to retatrutide 4 mg, 133 to retatrutide 9 mg, 136 to retatrutide 12 mg, and 134 to placebo. Baseline mean age was 48·8 years (SD 12·1), mean HbA concentration was 7·9% (SD 1·1), mean duration of diabetes was 2·5 years (SD 4·4), and mean BMI was 35·8 kg/m (SD 7·0). 490 (91%) participants completed the treatment period on study drug and 504 (94%) completed the study. For the treatment regimen estimand, the mean change from baseline in HbA concentration was -1·69% (SE 0·11) with retatrutide 4 mg, -1·86% (0·10) with 9 mg, and -1·94% (0·08) with 12 mg, versus -0·81% (0·12) with placebo, resulting in estimated treatment differences versus placebo of -0·88% (95% CI -1·18 to -0·59) with retatrutide 4 mg, -1·04% (-1·32 to -0·76) with 9 mg, and -1·12% (-1·39 to -0·85) with 12 mg (all p<0·0001). The mean percentage change from baseline in bodyweight was -11·5% (SE 0·7) with retatrutide 4 mg, -13·9% (0·8) with 9 mg, and -15·3% (0·8) with 12 mg, versus -2·6% (0·5) with placebo. The most frequent adverse events with retatrutide were generally mild to moderate gastrointestinal events, which subsided over time. Study intervention discontinuations due to adverse events were 2-5% with retatrutide and 0% with placebo. No severe hypoglycaemia was reported. Two deaths occurred during the study, both in the retatrutide 4 mg group and unrelated to the study drug. INTERPRETATION: Retatrutide showed significant improvements in glycaemic control and bodyweight reduction as a monotherapy in adults with type 2 diabetes that is inadequately controlled with diet and exercise alone, with an adverse event profile consistent with molecules with GLP-1 agonist activity, supporting its potential as an effective treatment for type 2 diabetes. FUNDING: Eli Lilly and Company.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.